Psyence Biomedical Ltd.
NASDAQ: PBM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jody Aufrichtig
- Employees
- 12
- Headquarters
- Toronto, Canada
- IPO year
- 2021
- Market cap
- $52.3K
- Website
- https://www.psyencebiomed.com
Loading PBM…
Loading profile data…Frequently asked questions about PBM
What does Psyence Biomedical Ltd. (PBM) do?
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule m...
Where does PBM trade?
Psyence Biomedical Ltd. (PBM) trades on the NASDAQ Capital Market.
What sector is PBM in?
Psyence Biomedical Ltd. (PBM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Psyence Biomedical Ltd.?
Jody Aufrichtig is the chief executive officer of Psyence Biomedical Ltd. (PBM).
Where is Psyence Biomedical Ltd. headquartered?
Psyence Biomedical Ltd. is headquartered in Canada.
Does PBM pay a dividend?
Psyence Biomedical Ltd. (PBM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PBM go public?
Psyence Biomedical Ltd. (PBM) completed its initial public offering in 2021.